Management of Involuntary Self-Mutilation in a Child with Lesch-Nyhan Syndrome
Article Sidebar
Main Article Content
Abstract
Lesch–Nyhan syndrome (LNS) is a rare X-linked recessive disorder of purine metabolism caused by deficiency of the enzyme hypoxanthine guanine phosphoribosyltransferase (HPRT). It is characterized by hyperuricemia, neurologic dysfunction, and self-mutilation. Medical and dental management in a 10-year-old boy diagnosed with LNS are described. Involuntary self-mutilation could be controlled using a soft mouth guard and repeated injections of botulinum toxin A (BTX-A) into the bilateral masseter and temporalis muscles. The findings suggest that patients with LNS require treatment from a multidisciplinary team. In addition, a soft mouth guard, repeated BTX-A injections, and pharmacological therapy could be a promising management of involuntary self-mutilation in LNS patients.
Article Details
บทความ ข้อมูล เนื้อหา รูปภาพ ฯลฯ ที่ได้รับการลงตีพิมพ์ในวิทยาสารทันตแพทยศาสตร์ มหาวิทยาลัยขอนแก่นถือเป็นลิขสิทธิ์เฉพาะของคณะทันตแพทยศาสตร์ มหาวิทยาลัยขอนแก่น หากบุคคลหรือหน่วยงานใดต้องการนำทั้งหมดหรือส่วนหนึ่งส่วนใดไปเผยแพร่ต่อหรือเพื่อกระทำการใด ๆ จะต้องได้รับอนุญาตเป็นลายลักษณ์อักษร จากคณะทันตแพทยศาสตร์ มหาวิทยาลัยขอนแก่นก่อนเท่านั้น
References
James WD, Berger TG, Elston DM. Andrews' Diseases of the Skin: clinical Dermatology. 11th ed. Saunders Elsevier; 2011.
Lesch M, Nyhan WL. A familial disorder of uric acid metabolism and central nervous system function. Am J Med 1964;36(4):561-70.
Crawhall JC, Henderson JF, Kelley WN. Diagnosis and treatment of the Lesch-Nyhan syndrome. Pediatr Res 1972;6(5):504-13.
Nyhan WL. The Lesch-Nyhan syndrome. Ann Rev Med 1973;24:41-60.
Lesch-Nyhan syndrome [database on the Internet]. Baltimore: Online Mendelian Inheritance in Man (OMIM), John Hopkins University; c1966-. [updated 2017 Sept 1; cited 2019 Aug 21]. Available from: http://www.omim.org/entry/300322.
Nyhan WL, O'Neill JP, Jinnah HA, Harris JC. Lesch-Nyhan Syndrome. In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, et al., editors. Gene Reviews (R). Seattle (WA); 1993 [updated 2014 May; cited 2019 Oct 18]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1149/.
Jinnah HA, Visser JE, Harris JC, et al. Delineation of the motor disorder of Lesch-Nyhan disease. Brain 2006;129(Pt 5):1201-17.
Cusumano FJ, Penna KJ, Panossian G. Prevention of self-mulitation in patients with Lesch-Nyhan syndrome: Review of literature. J Dent Child. 2001;68(3):175-78.
Bell S, Kolobova, Crapper L, Ernst C. Lesch-Nyhan Syndrome: Models, Theories, and Therapies. Mol Syndromol 2016;7(6):302-11.
Breese GR, Knapp DJ, Criswell HE, Moy SS, Papadeas ST, Blake BL. The neonate 6-hydroxydopamine lesioned rat: a model for clinical neuroscience and neurobiological principles. Brain Res Rev 2005; 48(1):57-73.
Smith BM, Cutilli BJ, Fedele M. Lesch-Nyhan Syndrome: A case report. Oral Surg Oral Med Oral Pathol 1994;78(3):317-318.
Christie R, Bay C, Kaufman IA, Bakay B, Borden M, Nyhan WL. Lesch-Nyhan disease: clinical experience with nineteen patients. Dev Med Child Neurol 1982;24(3):293-306.
Arhakis A, Topouzelis N, Kotsiomiti E, Kotsanos N. Effective treatment of self-injurious oral trauma in Lesch-Nyhan syndrome: a case report. Dent Traumatol 2010;26(6):496-500.
Lesch-Nyhan syndrome [database on the Internet]. Paris: Orphanet. [updated 2010 April; cited 2019 Dec 21]. Available from: https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=GB&Expert=510.
Dabrowski E, Smathers SA, Ralstrom CS, Nigro MA, Leleszi JP. Botulinum toxin as a novel treatment for self-mutilation in Lesch-Nyhan syndrome. Dev Med Child Neurol 2005;47(9):636-39.
Gutierrez C, Pellene A, Micheli F. Botulinum Toxin: Treatment of Self-Mutilation in Patients with Lesch-Nyhan Syndrome. Clin Neuropharmacol 2008;31(3): 180-83.
Goodman EM, Torres RJ, Puig JG, Jinnah HA. Consequences of Delayed Dental Extraction in Lesch-Nyhan Disease. Mov Disord Clin Pract 2014;1(3): 225-29.
Hladnik U, Nyhan WL, Bertelli M. Variable expression of HPRT deficiency in 5 members of a family with the same mutation. Arch Neurol 2008;65(9):1240-43.
Mitchell G, McInnes RR. Differential diagnosis of cerebral palsy: Lesch-Nyhan syndrome without self-mutilation. Can Med Assoc J 1984;130(10):1323-24.
Nyhan WL. Lesch-Nyhan disease. J Hist Neurosci 2005;14(1):1-10.
Nguyen KV, Naviaux RK, Paik KK, Nyhan WL. Novel mutations in the human HPRT gene. Nucleos Nucleot Nucl 2011;30(6):440-45.
Torres RJ, Puig JG. Hypoxanthine-guanine phosophoribosyltransferase (HPRT) deficiency: Lesch-Nyhan syndrome. Orphanet J Rare Dis 2007;2:48.
Torres RJ, Prior C, Puig JG. Efficacy and safety of allopurinol in patients with hypoxanthine-guanine phosphoribosyltransferase deficiency. Metabolism 2007;56(9):1179-86.
Olson L, Houlihan D. A review of behavioral treatments used for Lesch-Nyhan syndrome. Behav Modif 2000;24(2):202-22.
Chandekar P, Madke B, Kar S, Yadav N. Lesch-Nyhan Syndrome in an Indian Child. Indian J Dermatol 2015;60(3):298-300.
Harris JC. Lesch-Nyhan syndrome and its variants: examining the behavioral and neurocognitive phenotype. Curr Opin Psychiatry 2018;31(2):96-102.
McManaman J, Tam DA. Gabapentin for self-injurious behavior in Lesch-Nyhan syndrome. Pediatr Neurol 1999;20(5):381-82.
Eleopra R, Tugnoli V, Caniatti L, De Grandis D. Botulinum toxin treatment in the facial muscles of humans: evidence of an action in untreated near muscles by peripheral local diffusion. Neurology 1996;46(4):1158-60.
Taira T, Tomonori Kobayashi T, Hori T. Disappearance of self-mutilating behavior in a patient with Lesch–Nyhan syndrome after bilateral chronic stimulation of the globus pallidus internus Case report. J Neurosurg 2003;98(2):414-16.
Krack P, Vercucil L. Review of functional surgical treatment of dystonia. Eur J Neurol 2001;8(5):389-399.
Fardi K, Topouzelis N, Kotsanos N. Lesch-Nyhan syndrome: a preventive approach to self-mulitation. Int J Paediatr Dent 2003;13(1):51-56.